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Figure 5: P1 binding of cantharidin/
5HDG with residue labels. 
• Cantharidin has been shown to display anti-tumor properties 
through inhibitory activity on heat shock factor 1 protein (HSF1)¹.
• In the same study, norcantharidin displayed no inhibitory activity 
on the same protein.
• No literature on a binding site or binding strength is available at 
the time of this study.
• Our goal is to present potential binding sites and strengths for 
cantharidin and norcantharidin on HSF1 (PDB ID: 5HDG).
• Another goal is to supply binding energies to explain the 
inhibitory/non-inhibitory activity of cantharidin/norcantharidin on 
5HDG.
• Further studies forthcoming using GROMACS to account for 
protein structure changes and thus more accurate binding free 
energy.
• Increase number of ligands screened to determine most effective 
inhibitor of HSF1 while considering possible toxicities. 
• Synthesis of such ligands.
• More explicitly account for solvent interactions.
Protein Ligand Pocket
Binding Energy    
kcal · molˉ¹
5HDG Cantharidin P1 -4.75
5HDG Cantharidin P2 -4.65
5HDG Norcantharidin P1 -4.46
5HDG Norcantharidin P2 -4.09
• Two probable identical binding sites for 
both cantharidin and norcantharidin. 
• “Pocket 1” or P1 consisted of residues 
Val70, Leu73, Asn74, Phe99, Lys80, 
Phe78, and Arg79. 
• “Pocket 2” or P2 consisted of Ile35, 
Asp32, Cys36, Val26, Ser38, Trp37, 
Arg106, Pro29, Asp28, and Ser27.
• Simulations done assuming a rigid 
protein structure.
• It is unknown if P1/P2 is the active 
site of HSF1.
• Cantharidin-based compounds could prove to be even more 
effective HSF1 inhibitors than cantharidin.
• Based on binding energies ligand 5 (9) would be a compound to 
advance to further screening, ligand 3 (10) would not.
• Regardless of binding site, cantharidin consistently binds 
stronger to HSF1 than norcantharidin.
• Computational investigation reinforced the experimental 
evidence of cantharidin inhibitory activity on HSF1.
• Two potential binding sites (P1 and P2) were put forth for 
cantharidin-5HDG.
Figure 6: P1 binding of norcantharidin/
5HDG with residue labels.
Figure 1: Cantharidin. Figure 2: Norcantharidin. 
• Cantharidin hydrogen bond in 
area of LYS80 and ARG79 
• Norcantharidin hydrogen bond 
in area of ASN74
• Cantharidin bond to backbone (carboxyls/amines), 
norcantharidin to side chain.
• Lack of methyl groups could allow norcantharidin to settle in a 
different confirmation within P1 during docking.
• The binding energies may help explain why cantharidin inhibits 
HSF1 and norcantharidin does not.
Figure 7: Cantharidin hydrogen bonding (purple)
in P1. 
Figure 8: Norcantharidin hydrogen bonding 
(purple) in P1. 
Figure 3: Example of the full protein AutoGrid.  
Figure 4: Example of the P1 AutoGrid. 
Figure 9: Ligand 5 had a binding energies of -5.15
and -4.87 kcal mol ˉ¹ to 5HDG.  
Figure 10: Ligand 3 had binding energies of 
-4.47 and -4.08 kcal mol ˉ¹ to 5HDG. 
• Docking simulations through 
AutoDock 4.2².
• Ligand structure files 
generated using 
Avogadro/ORCA.
• Water molecules stripped 
from 5HDG, Gasteiger 
charges added
• AutoGrid with 0.425 
Angstrom spacing, failed 
dockings increased from 10 
to 25.
• Small GridBox in pocket, 
high AutoDock simulations 
• Ligand-protein renderings 
were done using the 
Chimera³.
Table 1: Summary of ligand-protein docking 
simulations in AutoDock.
